1. A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia
- Author
-
Benoît Delatte, Frank Kok, B. Gillain, J.-Y. Loze, Veronique Halkin, G. Touquet, A de Patoul, Chris Bervoets, Kristof Vansteelandt, Jozef Peuskens, and Eric Constant
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Aripiprazole ,Quinolones ,Uncontrolled Study ,Severity of Illness Index ,Piperazines ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Surveys and Questionnaires ,Internal medicine ,Clinical endpoint ,medicine ,Humans ,Prospective Studies ,Psychiatry ,Antipsychotic ,business.industry ,medicine.disease ,Confidence interval ,030227 psychiatry ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Treatment Outcome ,Tolerability ,Schizophrenia ,Quality of Life ,Female ,business ,030217 neurology & neurosurgery ,Antipsychotic Agents ,medicine.drug - Abstract
PurposeThe aim of this study is to evaluate the effectiveness of 12-week treatment with aripiprazole in a broad range of patients suffering from schizophrenia by using a variety of physicians, caregivers and patients scales.Subjects and methodsA total of 361 in- or outpatients who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia received open-label aripiprazole (10–30mg per day) in this 12-week, prospective, multicentre, uncontrolled study. The primary endpoint was the Clinical Global Impression-Improvement (CGI-I) scale which measured effectiveness of study medication, including efficacy, safety and tolerability. A variety of physician-, patient- and caregiver-rated parameters were measured to gain a complete view of the effectiveness of aripiprazole.ResultsThe effectiveness of aripiprazole treatment was demonstrated in a broad range of schizophrenia patients (CGI-I score of 3.0; 95% confidence interval: 2.8, 3.2: last observation carried forward [LOCF]) as the upper bound of the 95% CI was less than 4 (score of “no change”). Both patient and caregiver PGI-I scores (LOCF: 95% CI: 2.79, 3.09 and, 95% CI: 2.74, 3.17, respectively) corroborate this finding. Aripiprazole had a positive effect on disease severity by study end, as assessed by an increase of the (physician-rated) CGI-S scores, with 57.3% of patients having improved disease, one-third maintaining their condition (30.8%) and 11.3% with worsening symptoms (LOCF). The Investigator Assessment Questionnaire (IAQ) showed a great improvement (>50% of patients). Patients reported significantly improved quality of life and overall, 71% of patients and 67% of caregivers preferred aripiprazole to their previous antipsychotic medication (LOCF; PConclusionAripiprazole was effective in a broad range of patients with schizophrenia.
- Published
- 2012
- Full Text
- View/download PDF